More News

27 Jun 2022 Ipsen to acquire Epizyme, expanding its portfolio in oncology
24 Jun 2022 invoX Pharma to Acquire F-star Therapeutics, Inc. a Pioneering Next Generation Bispecific Discovery Platform and Clinical Programs
23 Jun 2022 Alpha Tau Announces Treatment of First Prostate Cancer Patient with Alpha DaRT
22 Jun 2022 Precision BioSciences Announces In Vivo Gene Editing Collaboration with Novartis to Develop Potentially Curative Treatment for Disorders Including Sickle Cell Disease
16 Jun 2022 Exelixis and BioInvent Establish Exclusive Option and License Agreement to Develop Novel Antibody-Based Immuno-Oncology Therapies
15 Jun 2022 Blue Earth Therapeutics Announces Promising Results of Preclinical Biodistribution and Efficacy Evaluation of 177Lu-rhPSMA-10.1 in Treatment of Prostate Cancer
15 Jun 2022 Boehringer Ingelheim signs Option to Acquire Trutino Biosciences
14 Jun 2022 D. E. Shaw Research Licenses First-in-Class Therapeutic for Immunological Diseases to Lilly
14 Jun 2022 Organon Enters into Global License Agreement to Commercialize Henlius’ Investigational Perjeta® (Pertuzumab) and Prolia®/Xgeva® (Denosumab) Biosimilar Candidates
13 Jun 2022 ImCheck Closes Upsized EUR 96 Million (USD 103 Million) Financing to Advance Clinical Program of First-in-human Gamma-delta T Cell Activating Antibody and Accelerate Development of Disruptive Immunotherapeutic Pipeline
10 Jun 2022 Degron Therapeutics Raises $22M Series A Financing to Accelerate Growth and Expand Molecular-Glue-Based Targeted Protein Degradation Drug Discovery Platform
08 Jun 2022 Immatics and Editas Medicine Enter Strategic Research Collaboration and Licensing Agreement to Combine Gamma-Delta T Cell Adoptive Cell Therapies and Gene Editing for the Treatment of Cancer
06 Jun 2022 Biogen and Alectos Therapeutics Announce License and Collaboration Agreement for AL01811, a Novel GBA2 Inhibitor for the Potential Treatment of Parkinson’s Disease
03 Jun 2022 Bristol Myers Squibb to Acquire Turning Point Therapeutics, a Leading Precision Oncology Company
03 Jun 2022 Boehringer Ingelheim enters global licensing agreement to develop and commercialize innovative antibodies from A*STAR for targeted cancer therapies
03 Jun 2022 Proxygen Announces Strategic Collaboration with Merck to Develop Molecular Glue Degraders
02 Jun 2022 Repare Therapeutics Announces a Worldwide License and Collaboration Agreement with Roche for Camonsertib (RP-3500)
02 Jun 2022 Immatics and Bristol Myers Squibb Expand Strategic Alliance to Develop Gamma Delta Allogeneic Cell Therapy Programs
01 Jun 2022 Astellas and GO Therapeutics Enter into Strategic Research and License Agreement to Develop Novel Antibodies for Immuno-Oncology
31 May 2022 GSK to acquire clinical-stage biopharmaceutical company Affinivax, Inc.
24 May 2022 KaliVir Immunotherapeutics Enters into Global Exclusive Licensing Agreement with Roche for Novel Oncolytic Viruses
23 May 2022 Innoviva to Acquire Entasis Therapeutics
20 May 2022 Cadherin 17-Targeted Novel Drug Modalities: a Target and Pipeline Review
19 May 2022 Myeloid Therapeutics Enters Into Agreement with Acuitas Therapeutics for Lipid Nanoparticle (LNP) System, Enabling the First-Ever Delivery of mRNA-Encoded CARs Directly to Humans
19 May 2022 Almirall and Evotec enter into a multi-target alliance in Medical Dermatology

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2022 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up